Feb 10, 2026
In this episode of JACC This Week, Dr. Harlan M. Krumholz and
Dr. Carolyn S.P. Lam discuss a dedicated issue of JACC focused on
cardiac amyloidosis—one of the fastest-evolving areas in
cardiovascular medicine.
They explore new evidence highlighting significant delays in
diagnosing ATTR cardiomyopathy, the early divergence of mortality
benefit with timely treatment, and why time to diagnosis is no
longer a neutral factor. The conversation also examines secondary
analyses from major clinical trials, practical guidance for
amyloidosis evaluation and management, and Dr. Krumholz’s Editor’s
Page on “computable diagnosis” as a moral imperative.
This episode places emerging science in clinical context,
emphasizing urgency, equity, and how clinicians should be thinking
differently about diagnosis, staging, and access to therapy in
amyloid heart disease.
Read Full issue here: https://www.jacc.org/toc/jacc/87/5
Keywords: cardiac amyloidosis, amyloid heart disease, ATTR
cardiomyopathy, computable diagnosis